Wall Street’s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields – Gilead Sciences (NASDAQ:GILD)
In times of market turbulence, many investors turn to dividend-yielding stocks, even when markets are at all-time highs. These stocks are often from companies with high free cash flows that reward shareholders with a high dividend payout.
Benzinga offers readers the latest analyst takes on their favorite stocks through the Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Here are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector:
1. Gilead Sciences, Inc. (GILD)
– Dividend Yield: 4.47%
– Baird analyst Brian Skorney maintained a Neutral rating with a price target of $80 on June 20. This analyst has an accuracy rate of 64%.
– RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on June 14. This analyst has an accuracy rate of 66%.
– Recent News: On June 26, Gilead Sciences Canada announced Phase 3 PURPOSE 1 Trial results.
2. CVS Health Corporation (CVS)
– Dividend Yield: 4.56%
– JP Morgan analyst Lisa Gill maintained an Overweight rating and cut the price target from $101 to $86 on May 30. This analyst has an accuracy rate of 60%.
– Argus Research analyst Chris Graja maintained a Buy rating and slashed the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 69%.
– Recent News: On May 1, CVS Health reported first-quarter sales of $88.4 billion, up 3.7% year over year. It missed the consensus of $89.21 billion.
3. Johnson & Johnson (JNJ)
– Dividend Yield: 3.40%
– Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on June 25. This analyst has an accuracy rate of 69%.
– B of A Securities analyst Geoff Meacham maintained a Neutral rating and cut the price target from $180 to $170 on April 17. This analyst has an accuracy rate of 62%.
– Recent News: On June 21, Johnson & Johnson announced the successful completion of the acquisition of Proteologix, Inc.
These high-yielding health care stocks offer investors opportunities for potential growth and dividend payouts. Investors can stay informed with Benzinga Pro’s real-time newsfeed and charting tools to make informed decisions about their investments.